Čes. slov. farm. 2016, 65(1):3-9 | DOI: 10.36290/csf.2016.001
The relationship of lipid imbalance and chronic inflammation mediated by PPAR
- Katedra bunkovej a molekulárnej biológie liečiv, Farmaceutická fakulta, Univerzita Komenského, Bratislava, Slovenská republika
Obesity is a serious metabolic disease that threatens patients with increasing incidence of the metabolic, cardiovascular, cancer1-3) and other associated, especially autoimmune diseases. It increases significantly the morbidity and mortality of patients and reduces quality of their life.
The imbalance between lipolysis and lipogenesis results in a number of metabolic related disorders at the different regulatory levels of transcription, translation, and/or activity of enzymes. One of the extensively studied areas in regulating lipogenesis, often accompanied by inflammation, is a peroxisome proliferator activated receptors (PPARs), especially its isomer PPAR-γ. PPAR-γ is a ligand-activated transcription factor belonging to the family of nuclear receptors. It is mostly presented in differentiated macrophages and adipose tissue5, 6). It has an important function of adipocyte differentiation and inflammation management in terms of gene expression inhibition of pro-inflammatory cytokines. PPAR-γ inhibition of inflammatory cytokines such as TNF-α may present the molecular mechanism of lipid disorders, thus contributing to the pathogenesis of various diseases, e.g. inflammation, insulin resistance and atherosclerosis, for which the lipid metabolism disorders are a common feature. Under the action of specific agonists, PPAR-γ alter the release of signal molecules from adipose tissue, which has far-reaching metabolic consequences in other tissues. It plays an important role in the inhibition of inflammation and the development of insulin resistance.
Keywords: obesity; inflammation; PPAR-γ; cytokines
Grants and funding:
Článok vznikol vďaka podpore v rámci OP Výskum a vývoj pre dopytovo-orientovaný projekt: Univerzitný vedecký park Univerzity Komenského v Bratislave, ITMS 26240220086 spolufinancovaný zo zdrojov Európskeho fondu regionálneho rozvoja a grantu FaF UK/12/2015.
Received: November 19, 2015; Accepted: February 1, 2016; Published: January 1, 2016 Show citation
References
- Berg A. H. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005; 96, 939-949.
Go to original source...
Go to PubMed...
- Wellen K. E. Inflammation, stress, and diabetes. J Clin Invest. 2005; 115: 1111-1119.
Go to original source...
Go to PubMed...
- Hossain P., Kawar B., El Nahas M. Obesity and diabetes in the developing world - a growing challenge. N Engl J Med. 2007; 356, 213-215.
Go to original source...
Go to PubMed...
- Czernichow S., Kengne A. P., Stamatakis E., Hamer M., Batty G. D. Body mass index, waist circumference and waist-hip ratio: which is the better discriminator of cardiovascular disease mortality risk?: evidence from an individual-participant meta-analysis of 82 864 participants from nine cohort studies. Obes Rev. 2011; 12, 680-687.
Go to original source...
Go to PubMed...
- Chen F. Biochem. Biophys. Res. Commun. 1993; 196, 671-677.
Go to original source...
Go to PubMed...
- Braissant O. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat Endocrinology 1996; 137, 354-366.
Go to original source...
- Finucane M. M., Stevens G. A., Cowan M. J. Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index). National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011; 377, 557-567.
Go to original source...
Go to PubMed...
- Controlling the global obesity epidemic http://www.who.int/nutrition/topics/obesity/en/ (25. 1. 16).
- Jernas M., Palming J., Sjoholm K. Separation of human adipocytes by size: hypertrophic fat cells display distinct gene expression. The FASEB Journal 2006; 20(9), 1540-1542.
Go to original source...
Go to PubMed...
- Farrel G. C., Larter C. Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatologyno. 2006; 43(Suppl 1), 99-112.
Go to original source...
Go to PubMed...
- Zimmet P., Magliano D., Matsuzawa Y., Alberti G., Shaw, J. The metabolic syndrome: a global public health problem and a new definition. J. Atheroscler. Thromb. 2005; 12, 295-300.
Go to original source...
Go to PubMed...
- Grundy S. M., Brewer Jr. H. B., Cleeman J. I., Smith Jr. S. C., Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109, 433-438.
Go to original source...
Go to PubMed...
- Ahima R. S., Flier J. S. Adipose tissue as an endocrine organ. Trends Endocrinol Metab. 2000; 11, 327-332.
Go to original source...
Go to PubMed...
- Fruhbeck G., Gomez-Ambrosi J., Muruzabal F. J., Burrell M. A. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab. 2001; 280, E827-E847.
Go to original source...
Go to PubMed...
- Klaus S. Adipose tissue as a regulator of energy balance. Curr Drug Targets. 2004; 5, 241-250.
Go to original source...
Go to PubMed...
- Frayn K. N., Karpe F., Fielding B. A., Macdonald I. A., Coppack S. W. Integrative physiology of human adipose tissue. Int J Obes Relat Metab Disord. 2003; 27, 875-888.
Go to original source...
Go to PubMed...
- Fain J. N., Madan A. K., Hiler M. L., Cheema P., Bahouth S. W. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145, 2273-2282.
Go to original source...
Go to PubMed...
- Rosen E. D., Spiegelman B. M. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol. 2000; 16, 145-171.
Go to original source...
Go to PubMed...
- Rosen E. D., Macdougald O. A. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol. 2006; 7, 885-896.
Go to original source...
Go to PubMed...
- Charriere G., Cousin B., Arnaud E., Andre M., Bacou F., Penicaud L., Casteilla L. Preadipocyte conversion to macrophage. Evidence of plasticity. J Biol Chem. 2003; 278, 9850-9855.
Go to original source...
Go to PubMed...
- Cousin B., Munoz O., Andre M., Fontanilles A. M., Dani C., Cousin J. L., Laharrague P., Casteilla L., Penicaud L. A role for preadipocytes as macrophage-like cells. FASEB J. 1999; 13, 305-312.
Go to original source...
Go to PubMed...
- Wellen K. E., Hotamisligil G. S. Inflammation, stress, and diabetes. J Clin Invest. 2005; 115, 1111-1119.
Go to original source...
Go to PubMed...
- Michalik L., Auwerx J., Berger J. P., Chatterjee V. K., Glass C. K., Gonzalez F. J., Grimaldi P. A., Kadowaki T., Lazar M. A., O'Rahilly S., Palmer C. N., Plutzky J., Reddy J. K., Spiegelman B. M., Staels B., Wahli W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 2006; 58(4), 726-741.
Go to original source...
Go to PubMed...
- Belfiore A., Genua M., Malaguarnera R. PPAR-gamma agonists and their effects on IGF-I receptor signaling: implications for cancer. PPAR Res. 2009; 2009: 830501.
Go to original source...
Go to PubMed...
- Berger J., Moller D. E. The mechanisms of action of PPARs. Annu. Rev. Med. 2002; 53, 409-435.
Go to original source...
Go to PubMed...
- Feige J. N., Gelman L., Michalik L., Desvergne B., Wahli W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res. 2006; 45(2), 120-159.
Go to original source...
Go to PubMed...
- Moreno S., Farioli-Vecchioli S., Cerù M. P. Immuno localization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 2004; 123, 131-145.
Go to original source...
Go to PubMed...
- Heneka M. T., Landreth G. E. PPARs in the brain. Biochim Biophys Acta 2007; 1771, 1031-1045.
Go to original source...
Go to PubMed...
- Lefebvre P., Chinetti G., Fruchart J. C., Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest. 2006; 116, 571-580.
Go to original source...
Go to PubMed...
- Rigamonti E., Chinetti-Gbaguidi G., Staels B. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler Thromb Vasc Biol. 2008; 28, 1050-1059.
Go to original source...
Go to PubMed...
- Barish G. D., Narkar V. A., Evans R. M. PPAR delta: A dagger in the heart of the metabolic syndrome. J Clin Invest. 2006; 116, 590-597.
Go to original source...
Go to PubMed...
- Graham T. L., Mookherjee C., Suckling K. E., Palmer C. N., Patel L. The PPAR delta agonist GW0742X reduces atherosclerosis in LDLR (-/-) mice. Atheroscerosis 2005; 181, 29-37.
Go to original source...
Go to PubMed...
- Ferre P. The biology of peroxisome proliferator-activated receptor. Diabetes 2004; 53, S43-50.
Go to original source...
Go to PubMed...
- Lehman J. M., Moore L. B., Smith-Oliver T. A., Wilkison W. O., Willson T. M., Kliewer S. A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor (PPAR gamma) J Biol Chem. 1995; 270, 12953-12956.
Go to original source...
Go to PubMed...
- Zhang H. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention Proc. Natl. Acad. Sci. USA 2005; 102, 9406-9411.
Go to original source...
Go to PubMed...
- Han S., Roman J. Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics? Anticancer Drugs 2007; 18, 439-445.
Go to original source...
Go to PubMed...
- Betteridge D. J. Thiazolidinediones and fracture risk in patients with type 2 diabetes Diabet. Med. 2011; 28, 759-771.
Go to original source...
Go to PubMed...
- Evans R. M., Barish G. D., Wang Y. X. PPARs and the complex journey to obesity. Nat Med. 2004; 10, 355-361.
Go to original source...
Go to PubMed...
- Shiraki T., Kamiya N., Shiki S., Kodoma T.S., Kakizuka A., Jingami H. αα,ββ-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor γγ. J Biol Chem. 2005; 280, 14145-14153.
Go to original source...
Go to PubMed...
- Harte A. L., Mcternan P. G., Mcternan C. L., Smith S. A., Barnett A. H., Kumar S. Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes. Diabetes Obes Metab. 2003; 5, 302-310.
Go to original source...
Go to PubMed...
- Di Gregorio G. B., Yao-Borengasser A., Rasouli N., Varma V., Lu T., Miles L. M., Ranganathan G., Peterson C. A., Mcgehee R. E., Kern P. A. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 2005; 54, 2305-2313.
Go to original source...
Go to PubMed...
- Hammarstedt A., Andersson C. X., Rotter Sopasakis V., Smith U. The effect of PPARγ ligands on the adipose tissue in insulin resistance. Prostaglandins Leukot Essent Fatty Acids. 2005; 73, 65-75.
Go to original source...
Go to PubMed...
- Harte A., Mcternan P., Chetty R., Coppack S., Katz J., Smith S., Kumar S. Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation 2005; 111, 1954-1961.
Go to original source...
Go to PubMed...
- Forman B. M., Chen J., Evans R. M. Hypolipidemic drugs, polyunsaturated fattyacids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci. 1997; 94(9), 4312-4317.
Go to original source...
Go to PubMed...
- Forman B. M., Tontonoz P., Chen J., Brun R. P., Spiegelman B. M., Evans R. M. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995; 83, 803-812.
Go to original source...
Go to PubMed...
- Kliewer S. A., Sundseth S. S., Jones S. A., Brown P. J., Wisely G. B., Koble C. S., Deychand P., Wahli W., Willson T. M., Lenhard J. M., Lehmann J. M. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci. 1997; 94, 4318-4323.
Go to original source...
Go to PubMed...
- Krey G., Braissant O., L'Horset F., Kalkhoven E., Perround M., Parker M. G., Wahli W. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol. 11, 1997; 779-791.
Go to original source...
Go to PubMed...
- Nagy L., Tontonoz P., Alvarez J. G., Chen H., Evans R. M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR-gamma. Cell 1998; 93, 229-240.
Go to original source...
Go to PubMed...
- Berger J., Leibowitz M. D., Doebber T. W., Elbrecht A., Zhang B., Zhou G., Biswas C., Cullinan C. A., Hayes N. S., Li Y., Tanen M., Ventre J., Wu M. S., Berger G. D., Mosley R., Marquis R., Santini C., Sahoo S. P., Tolman R. L., Smith R. G., Moller D. E. Novel peroxisome proliferator-activated receptor PPAR gamma and PPAR delta ligands produce distinct biological effects. J Biol Chem. 1999; 274, 6718-6725.
Go to original source...
Go to PubMed...
- Morino K., Petersen K. F., Shulman G. I. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 2006; 55(Suppl 2), 9-15.
Go to original source...
Go to PubMed...
- Pickup J. C., Crook M. A. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41, 1241-1248.
Go to original source...
Go to PubMed...
- Hotamisligil G. S. Inflammation and metabolic disorders. Nature 2006; 444, 860-867.
Go to original source...
Go to PubMed...
- Hevener A. L., Olefsky J. M., Reichart D., Nguyen M. T. A., Bandyopadyhay G., Leung H. Y., Watt M. J., Benner C., Febbraio M. A., Nguyen A. K., Folian B., Subramaniam S., Gonzalez F. J., Glass C. K., Ricote M. Macrophage PPARγ γ is required for normal skeltel muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest. 2007; 117, 1658-1669.
Go to original source...
Go to PubMed...
- Hotamisligil G. S., Arner P., Caro J. F., Atkinson R. L., Spiegelman M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995; 95(5), 2409-2415.
Go to original source...
Go to PubMed...
- Weisberg S. P., Mccann D., Desai M., Rosenbaum M., Leibel R. L., Ferrante Jr. A. W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112, 1796-1808.
Go to original source...
- Hotamisligil G. S., Shargill N. S., Spiegelman B. M. Adipose expression of tumor necrosis factor-αα: direct role in obesity-linked insulin resistance. Science 1993; 259(5091), 87-91.
Go to original source...
Go to PubMed...
- Toušková V., Haluzík M., Insulin resistance and nitric oxide: molecular mechanisms and pathophysiological associations. Československá fyziologie 2011; 60, 2.
- Yu Y. H., Ginsberg H. N. Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circulation Research 2005; 96(10), 1042-1052.
Go to original source...
Go to PubMed...
- Weisberg S. P., Hunter D., Huber R., Lemieux J., Slaymaker S., Vaddi K., Charo I., Leibel, R. L., Ferrante Jr. A. W. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest. 2006; 116, 115-124.
Go to original source...
Go to PubMed...
- Bruun J. M., Lihn A. S., Pedersen S. B., Richelsen B. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J Clin Endocrinol Metab. 2005; 90, 2282-2289.
Go to original source...
Go to PubMed...
- Kamei N., Tobe K., Suzuki R., Ohsugi M., Watanabe T., Kubota N., Ohtsuka- Kowatari N., Kumagai K., Sakamoto K., Kobayashi M., Yamauchi T., Ueki K., Oishi Y., Nishimura S., Manabe I., Hashimoto H., Ohnishi Y., Ogata H., Tokuyama K., Tsunoda M., Ide T., Murakami K., Nagai R., Kadowaki T. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 8. 2006; 281, 26602-26614.
Go to original source...
Go to PubMed...
- Sørensen T. L., Ransohoff R. M., Strieter R. M., Sellebjerg F. Chemokine CCL2 and chemokine receptor CCR2 in early active multiple sclerosis. Eur J Neurol. 2004; 11(7), 445-449.
Go to original source...
Go to PubMed...
- Hayashida K., Nanki T., Girschick H., Yavuz S., Ochi T., Lipsky P. E., Synovial stromal cells from rheumatoid arthritis patients attract monocytes by producing MCP-1 and IL-8. Arthritis Res. 2001; 3(2), 118-126.
Go to original source...
Go to PubMed...
- Kusano K. F., Nakamura K., Kusano H., Nishii N., Banba K., Ikeda T., Hashimoto K., Yamamoto M., Fujio H., Miura A., Ohta K., Morita H., Saito H., Emori T., Nakamura Y., Kusano I., Ohe T. Significance of the level of monocyte chemoattractant protein-1 in human atherosclerosis. Circ J. 2004; 68(7), 671-676.
Go to original source...
Go to PubMed...
- Sartipy P., Loskutoff D. J. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 2003; 100(12), 7265-7270.
Go to original source...
Go to PubMed...
- Hotamisligil G. S., Arner P., Caro J. F., Atkinson R. L., Spiegelman B. M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995; 95, 2409-2415.
Go to original source...
Go to PubMed...
- Kern P. A., Ranganathan S., Li C., Wood L., Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001; 280, E745-E751.
Go to original source...
Go to PubMed...
- Hotamisligil G. S. Inflammatory pathways and insulin action. International Journal of Obesity and Related Metabolic Disorders 2003; 27(Suppl 3), 53-55.
Go to original source...
Go to PubMed...
- Rotter V., Nagaev I., Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem. 2003; 278, 45777-45784.
Go to original source...
Go to PubMed...
- Aguirre V., Werner E. D., Giraud J., Lee Y. H., Shoelson S. E., White M. F. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem. 2002; 277, 1531-1537.
Go to original source...
Go to PubMed...
- Aguirre V., Werner E. D., Giraud J., Lee Y. H., Shoelson S. E., White M. F. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. Journal of Biological Chemistry 2002; 277(2), 1531-1537.
Go to original source...
Go to PubMed...
- Nguyen M. T. A., Satoh H., Favelyukis S. JNK and tumor necrosis factor-α mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. Journal of Biological Chemistry 2005; 280(42), 35361-35371.
Go to original source...
Go to PubMed...
- Gao Z., Hwang D., Bataille F. Serine phosphorylation of insulin receptor substrate 1 by inhibitor κB kinase complex. Journal of Biological Chemistry 2002; 277(504), 48115-48121.
Go to original source...
Go to PubMed...
- Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., Mori Y., Ide T., Murakimi K., Tsuboyma-Kasaoka N., Ezaki O., Akanuma Y., Gavrilova O., Vinson C., Reitman M. L., Kagechika H., Shudo K., Yoda M., Nakano Y., Tobe K., Nagai R., Kimura S., Tomita M., Froguel P., Kadowaki T. The fatderived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001; 7, 941-946.
Go to original source...
Go to PubMed...
- Chandran M., Phillips S. A., Ciaraldi T., Henry R. R. Adiponectin: more than just another fat cell hormone. Diabetes Care 2003; 26, 2442-2450.
Go to original source...
Go to PubMed...
- Dietze-Schroeder D., Sell H., Uhlig M., Koenen M., Eckel J. Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors. Diabetes 2005; 54, 2003-2011.
Go to original source...
Go to PubMed...
- Iwaki M., Matsuda M., Maeda N., Funahashi T., Matsuzawa Y., Makishima M., Shimomura I. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003; 52,1655-1663.
Go to original source...
Go to PubMed...
- Choi J. H., Banks A. S., Estall J. L., Kajimura S., Bostrom P., Laznik D., Ruas J. L., Chalmers M. J., Kamenecka T. M., Bluher M., Griffin P. R., Spiegelman B. M. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 2010; 466, 451-456.
Go to original source...
Go to PubMed...
- M., Liu F. Up- and down-regulation of adiponectin expression and ultimerization: Mechanisms and therapeutic implication. Biochimie 2012; 94: 2126-2130.
Go to original source...
Go to PubMed...
- Bajaj M., Suraamornkul S., Piper P., Hardies L. J., Glass L., Cersosimo E., Pratipanawatr T., Miyazaki Y., Defronzo R. A. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab. 2004; 89, 200-206.
Go to original source...
Go to PubMed...
- Bouskila M., Pajvani U. B., Scherer P. E. Adiponectin: a relevant player in PPARγγ-agonist-mediated improvements in hepatic insulin sensitivity? Int J Obes Relat Metab Disord. 2005; 29(Suppl 1), S17-S23.
Go to original source...
Go to PubMed...
- Xu H., Barnes G. T., Yang Q., Tan G., Yang D., Cchou C. J., Sole J., Nichols A., Ross J. S., Tartaglia L. A., Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003; 112: 1821-1830.
Go to original source...
- Kadowaki T. Yamauchi T. Adiponectin and adiponectin receptors. Endocrine Reviews 2005; 26(3), 439-451.
Go to original source...
Go to PubMed...
- Sharma A. M. Adipose tissue: a mediator of cardiovascular risk. Int J Obes Relat Metab Disord 2002; 26(Suppl 4), S5-S7.
Go to original source...
Go to PubMed...
- Toni R., Malaguti A., Castorina S., Roti E., Lechan R. M. New paradigms in neuroendocrinology: relationships between obesity, systemic inflammation and the neuroendocrine system. J Endocrinol Invest. 2004; 27, 182-186.
Go to original source...
Go to PubMed...
- Heielbronn L., Smith S. R., Ravussin E. Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int J Obes Relat Metab Disord. 2004; 28(Suppl 4), 12-21.
Go to original source...
Go to PubMed...
- Permana P. A., Menge C., Reaven P. D. Macrophage-secreted factors induce adipocyte inflammation and insulin resistance. Biochem Biophys Res Commun. 2006; 341, 507-514.
Go to original source...
Go to PubMed...
- Arkan M. C., Hevener A. L., Greten F. R. IKK-ββ links inflammation to obesity-induced insulin resistance. Nature Medicine 2005; 11(2), 191-198.
Go to original source...
Go to PubMed...
- Cai D., Yuan M., Frantz D. F. Local and systemic insulin resistance resulting from hepatic activation of IKK-ββ and NF-κκB. Nature Medicine 2005; 11(2), 183-190.
Go to original source...
Go to PubMed...
- Emanuelli B., Glondu M., Filloux C., Peraldi P., Van Obberghen E. The potential role of SOCS-3 in the interleukin-1ββ-induced desensitization of insulin signaling in pancreatic ββ-cells. Diabetes 2004; 53(Suppl 3), S97-S103.
Go to original source...
Go to PubMed...
- Rui L., Aguirre V., Kim J. K., Shulman G. I., Lee A., Corbould A., Dunaif A., White M.F. Insulin/IGF-1 and TNF-αα stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest. 2001; 107, 181-189.
Go to original source...
Go to PubMed...
- Weisberg S. P., Mccann D., Desai M., Rosenbaum M., Leibel R. L., Ferrante A. W. Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112: 1796-1808.
Go to original source...
- Li A. C., Palinovski W. Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis. Annu Rev Pharmacol Toxicol. 2006; 46, 1-39.
Go to original source...
Go to PubMed...
- Chinetti G., Zawadski C., Fruchart J. C., Staels B. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARαα, PPARγγ, and LXR. Biochem Biophys Res Commun. 2004; 314, 151-158.
Go to original source...
Go to PubMed...
- Tsuchida A., Yamauchi T., Takekawa S., Hada Y., Ito Y., Maki T., Kadowski T. Peroxisome proliferator-activated receptor (PPAR)αα activation increases adiponectin receptors and reduces obesity-related Inflammation in adipose tissue: comparison of activation of PPARαα, PPARγγ and their combination. Diabetes 2005; 54, 3358-3370.
Go to original source...
Go to PubMed...
- Kintscher U., Law R. E. PPARγγ-mediated insulin sensitization: the importance of fat versus muscle. Am J Physiol Endocrinol Metab. 2005; 288, E287-E291.
Go to original source...
Go to PubMed...
- Moller D. E., Berger, J. P. Role of PPARs in the regulation of obesity-relatedinsulin sensitivity and inflammation. Int J Obes Relat Metab Disord. 2003; 27(Suppl3), S17-S21.
Go to original source...
Go to PubMed...
- Evans R. M., Barish G. D., Wang Y. X. PPARs and the complex journey to obesity. Med. 2004; 10, 355-361.
Go to original source...
Go to PubMed...